A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine
Cephalalgia · 2024-04 · 44 (4)
DOI: 10.1177/03331024241232944 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cephalalgia, online erschienen am 24.04.2024. Verfasst von Robert Croop und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biohaven Pharmaceuticals, New Haven, CT, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Pyridines, Piperidines, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Biohaven.
Abstract (Originalsprache)
Background
The present study evaluated the long-term safety and tolerability of rimegepant, an orally administered small molecule calcitonin gene-related peptide receptor antagonist, in people with migraine.
Methods
This multicenter, long-term, open-label safety study included adults (≥18 years) with ≥1 year history of migraine who were sequentially enrolled into three groups: participants in the first two groups had either 2–8 or 9–14 moderate to severe migraine attacks per month by history and treated as needed ( pro re nata [PRN]) with one rimegepant 75 mg oral tablet up to once per calendar day for 52 weeks (PRN 2–8 and PRN 9–14); a third group, included to collect safety data during higher-frequency dosing, had 4–14 moderate to severe migraine attacks per month by history and who took one rimegepant tablet every other day as scheduled dosing plus PRN dosing of one rimegepant tablet for migraine attacks of any severity on nonscheduled dosing days for 12 weeks (every other day (EOD) + PRN).
Results
Overall, 1800 participants self-administered rimegepant (PRN 2–8: n = 1033; PRN 9–14: n = 481; EOD + PRN: n = 286). The most common on-treatment adverse events (AEs) were upper respiratory tract infection (8.8%), nasopharyngitis (6.8%) and sinusitis (5.1%). Most AEs were mild or moderate and considered unrelated to rimegepant. Serious AEs considered possibly (n = 1) or unlikely (n = 9) related to rimegepant were reported in ten (0.6%) participants. No signal of drug-induced liver injury because of rimegepant was identified.
Conclusions
Rimegepant 75 mg up to once per day as EOD + PRN for 12 weeks or PRN for up to 52 weeks was safe and well tolerated. No signal of hepatotoxicity, potential drug abuse, or medication-overuse headache was identified.
Trial registration
Clinicaltrials.gov: NCT03266588.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biohaven Pharmaceuticals, New Haven, CT, USA.
- Clinical Research Institute, Inc., Minneapolis, MN, USA.
- California Medical Clinic for Headache, Santa Monica, CA, USA.
- New England Institute for Neurology and Headache, Stamford, CT, USA.
- Pfizer, Inc., New York, NY, USA.
- Albert Einstein College of Medicine and the Montefiore Headache Center, Bronx, NY, USA.
ORCID-Profile: Richard B Lipton
Förderung
- Biohaven
Zitieren
APA
Croop, R., Berman, G., Kudrow, D., Mullin, K., Thiry, A., Lovegren, M., L'Italien, G., & Lipton, R. B. (2024). A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia, 44(4). https://doi.org/10.1177/03331024241232944
Vancouver
Croop R, Berman G, Kudrow D, Mullin K, Thiry A, Lovegren M, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024;44(4). doi:10.1177/03331024241232944
BibTeX
@article{Croop2024,
author = {Croop, Robert and Berman, Gary and Kudrow, David and Mullin, Kathleen and Thiry, Alexandra and Lovegren, Meghan and L'Italien, Gilbert and Lipton, Richard B},
title = {A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine},
journal = {Cephalalgia},
year = {2024},
volume = {44},
number = {4},
doi = {10.1177/03331024241232944}
}
EUVIMED